Phase II Double Blind Randomized Placebo Controlled Study of Sorafenib in Hormone Naive Biochemical Recurrence of Prostate Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 26 Aug 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 07 Jul 2008 New trial record.